Text resize

COUNTRY

ASPREE USA

Phone Icon

612-873-6905

FOR RESEARCHERS

The ASPREE trial of low-dose aspirin showed that 100mg of enteric coated aspirin taken daily did not extend life free of disability in older adults.

ASPREE XT is the continuing longitudinal follow-up of ASPREE participants seeking opportunities to prevent illness and disability in this age group.

THE ASPREE PROJECT

 

→ ASPREE Sub-studies

→ ASPREE Publications

→ Data Access

→ PI updates

THE ASPREE CLINICAL TRIAL  (March 2010 – June 2017)

ASPirin in Reducing Events in the Elderly (ASPREE) was a large community-based clinical trial undertaken between 2011 and 2017 involving older adults in the US and Australia. 19,114 individuals participated: 2,411 from centers across the US and 16,703 participants from across south eastern Australia. While the Australian participants were mainly Caucasians aged 70 and above, approximately half of US participants were ethnic minorities aged 65 years and older. At recruitment all participants were free of overt cardiovascular disease, dementia and physical disability.
The primary objective of ASPREE was to determine whether low-dose aspirin (100mg) could prolong disability-free survival, i.e. life free of dementia or persistent physical disability. Secondary objectives aimed to determine whether low-dose aspirin reduced the incidence of cardiovascular disease, cognitive decline, depression, cancer, physical disability and major bleeding episodes. The principal results were published in the New England Journal of Medicine in September 2018.

 

THE ASPREE-XT FOLLOW-UP STUDY  (June 2017 – current)

The ASPREE-XT study is continuing to follow-up the ASPREE participants following cessation of the randomized, aspirin or placebo, treatment phase. The large majority of participants are no longer taking aspirin. This phase of the study is aiming to determine whether any impacts of a prolonged course of aspirin therapy are delayed, as has been suggested with some cancers.  ASPREE-XT, in conjunction with various sub-studies is also examining whether genetic, lifestyle or environmental factors that may contribute to the maintenance of health and identify other opportunities to prevent illness and disability in this age group.

The Berman Center for Outcomes and Clinical Research leads the ASPREE project in the USA, and Monash University leads in Australia.

 

AT A gLANCE

 Project Features

  • Large community-based cohort, mostly aged >70 years at enrollment
  • RCT of 50% aspirin (100mg): 50% placebo for median 4.7 years
  • Standardized data collection and management
  • Endpoints adjudicated by clinical specialists blinded to treatment arm
  • High levels of compliance with study procedures and medication

ASPREE Sub-studies

ASPREE embedded a series of sub-studies into the project. These have explored the impact of low-dose aspirin on other conditions associated with aging including hearing loss, macular disease, bleeding and anemia.

Published sub-study papers include:  genomic studies, depression, epigenetics, falls and fractures, sepsis, and sex hormone studies in older women.

Documentation and data access

ASPREE Clinical Trial Protocol

Objectives and measures of the ASPREE clinical trial

  • The primary objective was to determine whether low-dose aspirin prolonged life free of dementia or persistent physical disability in the healthy elderly.
  • Secondary objectives related to the effects of low-dose aspirin on the key outcome areas of death, myocardial infarction/heart failure, stroke, dementia and cognitive decline, depression cancer, physical disability and major bleeding episodes.

Protocol summary

  • ASPREE was a double-blind, randomized, placebo-controlled primary prevention trial to determine whether daily active treatment of 100 mg enteric-coated aspirin extended the duration of disability-free life in healthy participants, mostly aged 70 years and above.
  • The study examined whether the potential benefits of low-dose aspirin (particularly the prevention of heart disease, stroke, certain cancers and dementia) outweighed the risks (particularly from GI bleeding and hemorrhagic stroke) in this age group.
  • Participants were eligible for the trial if they did not have a current clinical indication for aspirin (i.e. overt cardiovascular disease) or contraindication (i.e. allergy or increased risk of bleeding) and did not have dementia, significant physical disability, low hemoglobin levels, or a condition that was likely to be fatal during the 5 years of the trial. All were capable of providing informed consent.
  • Sample size estimate required 19,000 participants to provide 90% power of a true relative risk benefit of 0.90 for the primary endpoint (a composite of all-cause mortality, incident dementia and persistent physical disability) in an intention-to-treat analysis with an average follow-up of 5 years.
  • The trial received financial support from the National Institute on Aging and the National Cancer Institute (NIA and NCI; part of the National Institutes of Health in the USA), the National Health and Medical Research Council of Australia, Monash University and the Victorian Cancer Agency.
  • Bayer Pharma (Germany) provided in-kind support through the provision of low-dose aspirin and matching placebo and had no other involvement in the trial.

Download the ASPREE Clinical Trial Protocol

ASPREE-XT Study Protocol

Objectives and measures of the ASPREE follow up study, ASPREE-XT

  • The primary objective of ASPREE-XT is to determine whether there are delayed effects after a median 4.7 years of treatment with daily low-dose aspirin.  Suggestive evidence of such a ‘legacy’ effect has been identified with cancer and ASPREE-XT will provide an opportunity to confirm or refute this observation in a post clinical trial setting.
  • Similar observations will be made on other outcomes including all-cause mortality, physical disability, cancer, dementia and cognitive impairment, depression and frailty and the incidence of cardiovascular disease.
  • An additional objective is to study the impact of genomic, lifestyle and environmental factors on the maintenance of good physical and cognitive health amongst older adults.

Protocol summary

  • ASPREE-XT is a longitudinal, observational follow-up study of ASPREE participants.
  • The study will determine whether legacy effects of aspirin develop following an earlier period of treatment with low-dose aspirin.
  • An additional objective is to identify genomic, lifestyle and environmental factors that may contribute to the maintenance of good health in older adults.
  • Study methodology and measures are similar to that of the ASPREE clinical trial.
  • ASPREE-XT is funded by the National Institute on Aging  and the National Cancer Institute (NIA and NCI; part of the National Institutes of Health in the USA) and the National Health and Medical Research Council of Australia.
  • The study is conducted in community settings.

Download the ASPREE-XT study protocol

Data Access and Collaboration

ASPREE clinical trial data is managed through a partnership of USA and Australian study collaborators. Data is available to partnering and external researchers for projects of appropriate scientific merit. Expressions of interest to analyse data from the ASPREE clinical trial and/or sub-studies including biospecimens, are co-ordinated through the ASPREE Access Management Site (AMS).

The current list of approved projects in the AMS can be viewed here.

PI updates for researchers

ASPREE Update #8 (08.24.2021)

This brief update aims to keep researchers informed of developments with the ASPREE project. It is being sent to key ASPREE committee members, collaborators and end-point adjudicators. For further information about matters in this newsletter please feel free to contact a study PI.

Dear Colleagues,

ASPREE finds blood pressure variability linked to more rapid cognitive decline in older adults
Impact greatest in men receiving antihypertensive therapies
Adds to previous research showing similar findings in mid-life adults
Ernst ME et al. J Am Heart Ass 2021. DOI: 10.1161/JAHA.120.019613

Observational data from ASPREE shows no link between statin therapy and cognitive decline
Similar results from lipophilic and hydrophilic statins
More definitive results will come from large-scale statin trials currently progressing in older populations
Zhou Z et al. J Am Coll Cardiol 2021; 77(25):3145-56 DOI: 10.1016/j.jacc.2021.04.075

ASPREE finds that a polygenic risk score (PRS) effectively predicts risk of ischaemic stroke in older individuals
Strongest Individual predictors were age (AUC=59%), systolic BP (AUC=58%) & PRS (AUC=58%)
But PRS adds minimally to the risk score derived from composite of conventional risk factors
Neumann J T et al: Stroke 2021;52. DOI: 10.1161/STROKEAHA.120.033670

Distributed on behalf of the ASPREE PIs
John McNeil (john.mcneil@monash.edu)
Anne Murray AMurray@bermancenter.org)
Andy Chan (ACHAN@mgh.harvard.edu)
Danny Liew (danny.liew@monash.edu)

To subscribe to this newsletter please email john.mcneil@monash.edu.

View past ASPREE PI Updates

Page updated: August 24, 2021

NEWS FOR RESEARCHERS

Aspirin and cognitive decline

Aspirin and cognitive decline

Researchers at Monash University and the Berman Center for Outcomes and Clinical Research report that aspirin does not reduce the risk of Alzheimer’s disease, mild cognitive impairment, or cognitive decline in older adults.

Low-dose aspirin and depression

Low-dose aspirin and depression

Daily low-dose aspirin does not prevent depression in healthy older adults, reports the ASPREE-D (depression) sub-study, the first detailed investigation of its kind.

Observational statin study in ASPREE participants

Observational statin study in ASPREE participants

First-line cholesterol-lowering drugs known as statins are associated with fewer heart attacks and strokes, but not associated with a prolonged life free of physical disability or dementia in healthy older adults, an ASPREE analysis shows.

For researchers